RICHMOND, British Columbia, July 8, 2010 (GLOBE NEWSWIRE) -- BioCurex Inc. (OTCBB:BOCX ) today announced its first set of results supporting the use of the BioCurex RECAF blood test to monitor cancer therapy. The test included samples from 27 human patients with early stages of breast cancer that were tested before and after surgery. As a control, 15 samples from healthy individuals were also tested.
